Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Literature
1.
Zhao H, Wilkie T, Deol Y, Sneh A, Ganju A, Basree M, et al. miR-29b defines the pro-/anti-proliferative effects of S100A7 in breast cancer. Mol Cancer. 2015;14:11.PubMedCentralCrossRefPubMed
Metadata
Title
Erratum to: miR-29b defines the pro-/anti-proliferative effects of S100A7 in breast cancer
Publication date
01-12-2015
Published in
Molecular Cancer / Issue 1/2015
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-015-0451-9

Other articles of this Issue 1/2015

Molecular Cancer 1/2015 Go to the issue

Research

Modulation of extracellular matrix in cancer is associated with enhanced tumor cell targeting by bacteriophage vectors

Research

NF-κB induces miR-148a to sustain TGF-β/Smad signaling activation in glioblastoma

Research

Aryl hydrocarbon receptor-microRNA-212/132 axis in human breast cancer suppresses metastasis by targeting SOX4

Short communication

Erk2 but not Erk1 regulates crosstalk between Met and EGFR in squamous cell carcinoma cell lines

Research

The anti-angiogenic and cytotoxic effects of the boswellic acid analog BA145 are potentiated by autophagy inhibitors

Research

Human papillomavirus mediated inhibition of DNA damage sensing and repair drives skin carcinogenesis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits